Centessa 2.0 with a twist: Medicxi combines six immuno-derm startups with $100M
European biotech investor Medicxi is bringing six startups under one roof to form an immuno-dermatology drugmaker with 14 pipeline projects in a move reminiscent of its 10-in-1 Centessa Pharmaceuticals unveiling in 2021.
The healthcare investment firm will pump $100 million in financing into the Boston and Geneva-based biotech named Alys Pharmaceuticals. It’s an amalgamation of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. Those make up the majority of the seven immuno-derm startups Medicxi invested in over the past few years, but the first, vitiligo drugmaker Villaris Therapeutics, already sold to Incyte.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.